caa a22 4500 605520380 CHVBK 20210128100735.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s00223-015-0007-4 doi (NATIONALLICENCE)springer-10.1007/s00223-015-0007-4 Teriparatide Therapy Reduces Serum Phosphate and Intima-Media Thickness at the Carotid Wall Artery in Patients with Osteoporosis [Elektronische Daten] [Maki Yoda, Yasuo Imanishi, Yuki Nagata, Masaya Ohara, Koichiro Yoda, Shinsuke Yamada, Katsuhito Mori, Masaaki Inaba] Although cross-sectional and longitudinal studies report a relationship between osteoporosis and cardiovascular disorders (known as the bone-cardiovascular axis), the benefits of osteoporosis treatment on atherosclerosis are largely unclear. Teriparatide is a bone-forming agent that increases urinary phosphate excretion. Because elevated serum phosphate is associated with the development of atherosclerosis, the purpose of our study was to examine the relationship among lumbar spine bone mineral density (LS-BMD), intima-media thickness at the carotid artery (CA-IMT), and phosphate metabolism in response to daily teriparatide therapy. Osteoporotic patients (n = 28) with low LS-BMD (T-score < −2.5) and/or at least one vertebral fracture were treated with teriparatide (20μg/day) for 12months. Metabolic bone markers, LS-BMD, and CA-IMT were measured over the course of treatment. The LS-BMD significantly increased by 0.046 ± 0.038g/cm2 over the 12-month period (P < 0.001). CA-IMT decreased from 0.701mm (interquartile range: 0.655-0.774mm) at baseline to 0.525mm (0.477-0.670mm) at 12months (P < 0.05); however, CA-IMT change was not significantly associated with LS-BMD change. Serum phosphate decreased after 1month of teriparatide administration, and the change in serum phosphate at 1months was associated with the change in CA-IMT at 12months (ρ = 0.431, P = 0.025). Teriparatide improved LS-BMD and CA-IMT, suggesting the existence of the bone-cardiovascular axis. The association between serum phosphate and CA-IMT suggests that the teriparatide decreased CA-IMT in part by reducing serum phosphate, a well-known vascular toxin, in addition to the improvement of bone-cardiovascular axis. Springer Science+Business Media New York, 2015 Atherosclerosis nationallicence Intima-media thickness nationallicence Osteoporosis nationallicence Phosphate nationallicence Teriparatide nationallicence Yoda Maki Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut Imanishi Yasuo Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut Nagata Yuki Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut Ohara Masaya Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut Yoda Koichiro Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut Yamada Shinsuke Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut Mori Katsuhito Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut Inaba Masaaki Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut Calcified Tissue International Springer US; http://www.springer-ny.com 97/1(2015-07-01), 32-39 0171-967X 97:1<32 2015 97 223 https://doi.org/10.1007/s00223-015-0007-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00223-015-0007-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yoda Maki Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Imanishi Yasuo Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Nagata Yuki Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Ohara Masaya Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Yoda Koichiro Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Yamada Shinsuke Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Mori Katsuhito Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 700 1- Inaba Masaaki Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan aut NATIONALLICENCE 773 0- Calcified Tissue International Springer US; http://www.springer-ny.com 97/1(2015-07-01), 32-39 0171-967X 97:1<32 2015 97 223